Endeavor II Four-Year Results Demonstrate Long-Term Safety And Durable Efficacy Of Medtronic Drug-Eluting Stent
May 15th 2008Drug InformationCardiovascular
Today at EuroPCR, Medtronic, Inc. (NYSE: MDT), released four-year data from the ENDEAVOR II clinical trial that reinforces the long-term safety and durable efficacy of the company’s Endeavor Zotarolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. “As the duration of follow-up in ENDEAVOR II grows, so too does our confidence in the enduring safety and effectiveness of the Endeavor stent,” said Dr.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
